Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Dittrich

Showing results (161-170 of 229) with videos related to

Pageof 23
Sort By:
Wiener Klinische Wochenschrift|January 21, 1983
[Pharmacokinetics and acute signs of cardiac toxicity during doxorubicin therapy]R Lenzhofer, B Schneeweiss, H Rameis, et al.
Acta Radiologica. Supplementum|January 1, 1986
Blood brain barrier modification and chemotherapy. Interventional neuroradiology in the treatment of malignant gliomasK Heimberger, P Samec, H Binder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2001
Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminomaM De Santis, C Bokemeyer, A Becherer, et al.
European Journal of Cancer (Oxford, England : 1990)|February 5, 2003
Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancerC Dittrich, B Coudert, L Paz-Ares, et al.
The American Journal of Physiology|August 1, 1978
Increased in blood flow to ischemic myocardium caused by a new dopamine analogJ N Diana, B C Brenton, J P Long, et al.
Cancer Letters|May 1, 1997
Tyrosine kinase signaling pathways control the expression of retinoic acid receptor-alpha in SK-BR-3 breast cancer cellsS H Flicker, S M Schneider, M Offterdinger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 2008
Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI GroupD Arnold, T Höhler, C Dittrich, et al.
Cardiology|October 22, 2009
Physician-determined worsening heart failure: a novel definition for early worsening heart failure in patients hospitalized for acute heart failure--association with signs and symptoms, hospitalization duration, and 60-day outcomesGad Cotter, Marco Metra, Beth Davison Weatherley, et al.
Geburtshilfe Und Frauenheilkunde|November 1, 1985
[Results of the first Austrian multicenter ovarian cancer study: prospective randomized comparison of sequential chemotherapy (adriamycin/cisplatin--vincristine/cyclophosphamide--methotrexate) with 2 standard protocols (adriamycin/cyclophosphamide or adriamycin/cisplatin) in stage III and IV patients]H Salzer, E Gitsch, C Dittrich, et al.
Oncology Letters|September 12, 2012
Chemoradiotherapy with 5-fluorouracil/leucovorin, surgery and adjuvant chemotherapy for locally advanced rectal cancerM Baur, M Horvath, S Stättner, et al.
Pageof 23

Showing results (161-170 of 229) with videos related to

Sort By:
Pageof 23
Wiener Klinische Wochenschrift|January 21, 1983
[Pharmacokinetics and acute signs of cardiac toxicity during doxorubicin therapy]R Lenzhofer, B Schneeweiss, H Rameis, et al.
Acta Radiologica. Supplementum|January 1, 1986
Blood brain barrier modification and chemotherapy. Interventional neuroradiology in the treatment of malignant gliomasK Heimberger, P Samec, H Binder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2001
Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminomaM De Santis, C Bokemeyer, A Becherer, et al.
European Journal of Cancer (Oxford, England : 1990)|February 5, 2003
Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancerC Dittrich, B Coudert, L Paz-Ares, et al.
The American Journal of Physiology|August 1, 1978
Increased in blood flow to ischemic myocardium caused by a new dopamine analogJ N Diana, B C Brenton, J P Long, et al.
Cancer Letters|May 1, 1997
Tyrosine kinase signaling pathways control the expression of retinoic acid receptor-alpha in SK-BR-3 breast cancer cellsS H Flicker, S M Schneider, M Offterdinger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 2008
Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI GroupD Arnold, T Höhler, C Dittrich, et al.
Cardiology|October 22, 2009
Physician-determined worsening heart failure: a novel definition for early worsening heart failure in patients hospitalized for acute heart failure--association with signs and symptoms, hospitalization duration, and 60-day outcomesGad Cotter, Marco Metra, Beth Davison Weatherley, et al.
Geburtshilfe Und Frauenheilkunde|November 1, 1985
[Results of the first Austrian multicenter ovarian cancer study: prospective randomized comparison of sequential chemotherapy (adriamycin/cisplatin--vincristine/cyclophosphamide--methotrexate) with 2 standard protocols (adriamycin/cyclophosphamide or adriamycin/cisplatin) in stage III and IV patients]H Salzer, E Gitsch, C Dittrich, et al.
Oncology Letters|September 12, 2012
Chemoradiotherapy with 5-fluorouracil/leucovorin, surgery and adjuvant chemotherapy for locally advanced rectal cancerM Baur, M Horvath, S Stättner, et al.
Pageof 23